{"product_id":"lucicob-cobimetinib","title":"LuciCob (Cobimetinib)","description":"\u003ch2\u003eAbout Cobimetinib \u003c\/h2\u003e\u003cp\u003eCobimetinib is a MEK inhibitor. Cobimetinib is an anti-cancer medication used to treat melanoma and histiocytic neoplasms. \u003c\/p\u003e\u003ch3\u003eMelanoma\u003c\/h3\u003e\u003cp\u003eIndicated for unresectable or metastatic melanoma in patients with a BRAF V600E or V600K mutation, in combination with vemurafenib\u003c\/p\u003e\u003cp\u003e60 mg PO qDay for the first 21 days of each 28-day cycle until disease progression or unacceptable toxicity\u003c\/p\u003e\u003cp\u003eVemurafenib: 960 mg PO BID on days 1-28 of an every 28-day cycle\u003c\/p\u003e\u003ch3\u003eHistiocytic Neoplasms\u003c\/h3\u003e\u003cp\u003eIndicated as a single agent for adults with histiocytic neoplasms\u003c\/p\u003e\u003cp\u003e60 mg PO qDay for the first 21 days of each 28-day cycle until disease progression or unacceptable toxicity\u003c\/p\u003e\u003ch3\u003eDosage Modifications\u003c\/h3\u003e\u003cp\u003eNew primary malignancies (cutaneous and noncutaneous): No dosage modification required\u003c\/p\u003e\u003cp\u003eAvoid concurrent use of cobimetinib and strong or moderate CYP3A inducers including but not limited to carbamazepine, efavirenz, phenytoin, rifampin, and St. John’s Wort\u003c\/p\u003e\u003ch4\u003eHepatic impairment\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eMild-to-severe (Child-Pugh A to C): No dosage adjustment necessary\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003eRenal impairment\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eMild-to-moderate (CrCl 30-89 mL\/min): No dosage adjustment necessary\u003c\/li\u003e\n\u003cli\u003eSevere (CrCl \u0026lt;30 mL\/min): Safety and efficacy not established\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eCoadministration with CYP3A inhibitors\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eDo not take strong or moderate CYP3A inhibitors while taking cobimetinib\u003c\/li\u003e\n\u003cli\u003eIf concurrent short-term (≤14 days) use of moderate CYP3A inhibitors is unavoidable for patients taking cobimetinib 60 mg, reduce dose to 20 mg; after the moderate CYP3A inhibitor is discontinued, resume previous cobimetinib dose\u003c\/li\u003e\n\u003cli\u003eUse an alternative to a strong or moderate CYP3A inhibitor in patients who are taking a reduced dose of cobimetinib (40 or 20 mg daily)\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eDose reductions\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eFirst dose reduction: 40 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eSecond dose reduction: 20 mg PO qDay\u003c\/li\u003e\n\u003cli\u003eSubsequent modification: Permanently discontinue cobimetinib if unable to tolerate 20-mg dose\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHemorrhage\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eGrade 3: Withhold cobimetinib for up to 4 wk; if improved to grade 0 or 1, resume at the next lower dose level; permanently discontinue if not improved within 4 wk\u003c\/li\u003e\n\u003cli\u003eGrade 4: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eCardiomyopathy\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eAsymptomatic\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eDefinition: Absolute decrease in LVEF from baseline of \u0026gt;10% and less than institutional lower limit of normal (LLN) Withhold cobimetinib for 2 wk; repeat LVEF\u003c\/li\u003e\n\u003cli\u003eResume at next lower dose if all of the following are present: LVEF is ≥LLN and absolute decrease from baseline LVEF is ≤10%\u003c\/li\u003e\n\u003cli\u003ePermanently discontinue if any of the following are present: LVEF is 10%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eSymptomatic LVEF decrease from baseline\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold cobimetinib for 4 wk; repeat LVEF\u003c\/li\u003e\n\u003cli\u003eResume at next lower dose if all of the following are present:\u003c\/li\u003e\n\u003cli\u003eSymptoms resolve and LVEF is ≥LLN and absolute decrease from baseline LVEF is ≤10%\u003c\/li\u003e\n\u003cli\u003ePermanently discontinue if any of the following are present:\u003c\/li\u003e\n\u003cli\u003eSymptoms persist, or LVEF is 10%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eDermatologic reactions\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eGrade 2 (intolerable) or grades 3 or 4: Withhold or reduce dose\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003eRetinopathy or retinal vein occlusion\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eSerous retinopathy: Withhold for up to 4 wk; if signs and symptoms improve, resume at the next lower dose level; permanently discontinue if not improved or symptoms recur at the lower dose within 4 wk\u003c\/li\u003e\n\u003cli\u003eRetinal vein occlusion: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eHepatoxicity\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003eFirst occurrence grade 4: Withhold for up to 4 wk; if improved to grade 0 or 1, resume at the next lower dose level; permanently discontinue if not improved within 4 wk\u003c\/li\u003e\n\u003cli\u003eRecurrent grade 4: Permanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch4\u003eRhabdomyolysis and elevated CPK\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eGrade 4 creatine phosphokinae (CPK) elevation or any CPK elevation plus myalgia: Withhold for up to 4 wk; if improved to ≤grade 3, resume at the next lower dose level; permanently discontinue if not improved within 4 wk\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003ePhotosensitivity\u003c\/h4\u003e\u003cul\u003e\u003cli\u003eGrade 2 (intolerable), grades 3 or 4: Withhold for up to 4 wk; if improved to grade 0 or 1, resume at the next lower dose level; permanently discontinue if not improved within 4 wk\u003c\/li\u003e\u003c\/ul\u003e\u003ch4\u003eOther adverse events\u003c\/h4\u003e\u003cul\u003e\n\u003cli\u003e\n\u003ch5\u003eGrade 2 (intolerable) adverse reactions or any grade 3\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003eWithhold for up to 4 wk; if improved to grade 0 or 1, resume at the next lower dose level; permanently discontinue if not improved within 4 wk\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eFirst occurrence of any grade 4 adverse reaction\u003c\/h5\u003e\n\u003cul\u003e\n\u003cli\u003eWithhold until adverse reaction improves to grade 0 or 1 and then resume at the next lower dose level, OR\u003c\/li\u003e\n\u003cli\u003ePermanently discontinue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003ch5\u003eRecurrent grade 4 adverse reaction\u003c\/h5\u003e\n\u003cul\u003e\u003cli\u003ePermanently discontinue\u003c\/li\u003e\u003c\/ul\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Lucius Pharmaceuticals (Lao) Co., Ltd","offers":[{"title":"Default Title","offer_id":44797957832747,"sku":"RL3520250416","price":0.0,"currency_code":"AMD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0701\/3528\/3755\/files\/2025-04-1325.jpg?v=1787022292","url":"https:\/\/xomeds.com\/products\/lucicob-cobimetinib","provider":"XOMEDS","version":"1.0","type":"link"}